Original Source(s)
Related Content
FDA approves serial liquid biopsy testing
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026
-
2 min
Cancer Screening Gaps Seen in Sexual, Gender Minority Groups
A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.
July 9, 2026
-
5 min